Loading...
Loading...
COSCIENS Biopharma Inc.
COSCIENS Biopharma Inc.. Spoken Alpha tracks CSCIF's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks CSCIF's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 80% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for CSCIF.
curl https://api.spokenalpha.com/v1/companies/CSCIF| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $3.26 | $2.76 | +18.2% | +8.0% | +6.5% |
| Q4 FY2026 | $3.24 | $2.93 | +10.6% | +3.3% | +0.3% |
| Q3 FY2026 | $3.23 | $2.96 | +9.1% | +4.6% | +5.9% |
| Q2 FY2026 | $3.43 | $3.07 | +11.6% | -0.7% | 0.0% |
| Q1 FY2025 | $3.33 | $2.87 | +15.9% | +8.9% | +8.3% |
| Q4 FY2025 | $3.47 | $3.02 | +14.9% | -1.7% | +1.0% |
| Q3 FY2025 | $3.21 | $2.87 | +12.0% | +5.3% | +8.0% |
| Q2 FY2025 | $3.44 | $3.05 | +12.9% | +8.2% | +10.6% |
| Q1 FY2024 | $3.48 | $3.02 | +15.2% | +6.7% | +5.6% |
| Q4 FY2024 | $3.60 | $3.07 | +17.3% | +0.9% | -1.9% |